Transplantation
News
Dasatinib outcomes similar to imatinib in pediatric Ph+ ALL
Dasatinib used during induction and consolidation in the Children’s Oncology Group (COG) AALL0622 trial provided early response rates for children...
News
Cytotect®CP found to be safe and effective after allo-HCT
A small retrospective study of 23 transplant patients has confirmed that CMV hyperimmune globulin (Cytotect®CP) is a safe and effective salvage...
News
A closer look at the BK polyomavirus
A detailed image at near-atomic levels of the BK polyomavirus (BKV), which affects kidney and bone marrow transplant patients, is now available...
News
Older, cheaper drug formulation to remain available
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and...
News
MSC product can treat refractory GVHD
MONTRÉAL—Results from a phase 3 trial suggest a mesenchymal stem cell (MSC) product can treat steroid-refractory, acute graft-versus-host disease...
News
CAR T-cell therapy bridges to HSCT in AML patient
A case report suggests an investigational chimeric antigen receptor (CAR) T-cell therapy can provide a bridge to transplant in relapsed/refractory...
News
JAK inhibitor reduces GVHD in mice
An investigational JAK1/2 inhibitor can fight graft-versus-host disease (GVHD), according to preclinical research published in Leukemia. The...
News
Drug receives breakthrough designation for HSCT-TMA
The US Food and Drug Administration (FDA) has granted a second breakthrough therapy designation to OMS721. OMS721 is a monoclonal antibody...
News
Haplo-HSCT regimen can cure SCD, team says
A haploidentical transplant regimen has led to long-term engraftment in adults with sickle cell disease (SCD), according to researchers. Seven of...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
News
FDA lifts hold on trials of BPX-501
The US Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the US. BPX-501 is an adjunct T-cell therapy...